Last updated: 2026-09-09 10:37:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
TransMedics Group, Inc. (TMDX) operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $87,65, with a market capitalization of $3,12B and a P/E ratio of 20,18. Over the past 52 weeks, its price has ranged from $60,11 to $156,00. This page covers its latest market performance, valuation, price trends and company information.
$3,12B | |
$88,85 | |
$177,37 | |
$10,00 | |
$88,27 | |
282,00 | |
928,12K | |
20,18 | |
$156,00 | |
$60,11 | |
-- | |
-- |
TransMedics Group, Inc. (TMDX) is trading at $87,65 in pre-market trading as of 2026-09-09 10:01:00, down 0,71% ($0,63) from the previous close of $88,27
Pre-market trading shows how investors are pricing TMDX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, TransMedics Group, Inc. (TMDX) moved from $88,43 to $87,65, representing a decline of 0,89% ($0,79).
The stock traded between $81,34 and $93,45 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 714,66 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 28,7%
TMDX is currently trading at $87,65, placing it 28,7% of the way from its 52-week low of $60,11 to its 52-week high of $156,00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
| Industry | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees | 898 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of TransMedics Group, Inc. (TMDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.